申请人:Aska Pharmaceutical Co., Ltd.
公开号:US08193356B2
公开(公告)日:2012-06-05
The compound of the present invention is a novel compound which has a specific heterocycle skeleton, particularly a pyrazolonaphthyridine or pyrazoloquinoline skeleton having an organic group (e.g., a carbocycle and a heterocycle) bonding through an alkylene group at 3-position and a carbocycle bonding at 5-position and has a phosphodiesterase IV inhibitory activity. At least one of the ring (the carbocycle or the heterocycle) bonding at 3-position of the pyrazolonaphthyridine skeleton and the carbocycle bonding at 5-position may have a halogenated alkyl group and/or a halogenated alkoxy group as a substituent. Such a compound or a salt thereof is useful as a phosphodiesterase IV inhibitor and the like. According to the present invention, a novel compound having a high phosphodiesterase IV inhibitory effect can be provided.
本发明的化合物是一种具有特定杂环骨架的新型化合物,特别是具有通过3位的烷基与5位的碳环键合的有机基团(例如,碳环和杂环)的吡唑啉萘或吡唑喹啉骨架,并具有磷酸二酯酶IV抑制活性。在吡唑啉萘骨架的3位和5位的碳环键合中,至少一个环(碳环或杂环)可能具有卤代烷基和/或卤代烷氧基作为取代基。这样的化合物或其盐对于磷酸二酯酶IV抑制剂等具有用途。根据本发明,可以提供一种具有高磷酸二酯酶IV抑制效果的新型化合物。